Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07542548 · ClinicalTrials.gov registry record · Phase 4
D-Cycloserine for Serine Palmitoyltransferase Inhibition
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT07542548: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT07542548 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07542548, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
Primary Outcome
Frequency of treatment related serious adverse events as assessed by CTCAE Version 5.0
Interventions
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 4 |
What the finished NCT07542548 record still lists
NCT07542548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which D-cycloserine is the first listed.
NCT07542548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07542548 about?
NCT07542548 is a clinical study titled "D-Cycloserine for Serine Palmitoyltransferase Inhibition". The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
What is the current status of trial NCT07542548?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2024-07-10. Estimated completion is 2026-03-17.
What interventions are being tested in trial NCT07542548?
The interventions under investigation include: D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT07542548?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07542548's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI